In vitro susceptibility of nonfermenting Gram-negative rods to meropenem–vaborbactam and delafloxacin - Archive ouverte HAL Access content directly
Journal Articles Future Microbiology Year : 2023

In vitro susceptibility of nonfermenting Gram-negative rods to meropenem–vaborbactam and delafloxacin

Eric Farfour
Louise Ruffier d'Epenoux
  • Function : Author
Corentine Alauzet
  • Function : Author
Lise Crémet
  • Function : Author
Sophie Moussalih
  • Function : Author
Antoine Roux
  • Function : Author
Sylvie de Verdière
  • Function : Author
Amélie Bosphore
  • Function : Author
Stéphane Corvec
  • Function : Author
Marc Vasse
  • Function : Author

Abstract

Aim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. ( Achr), Burkholderia cepacia complex ( Bcc) and Stenotrophomonas maltophilia ( Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with gradient diffusion test of meropenem–vaborbactam, delafloxacin and comparators. Results: Meropenem–vaborbactam MIC 50 were 4 μg/ml for Achr, 1 μg/ml for B. cepacia, 2 μg/ml for B. cenocepacia and B. multivorans, and 32 μg/ml for Smal. Delafloxacin MIC 50 were 4 μg/ml for Achr, 0.25 μg/ml for B. cepacia and B. multivorans, 2 μg/ml for B. cenocepacia, and 0.5 μg/m for Smal. meropenem–vaborbactam MICs were fourfold lower than meropenem for 28.3% Achr, 77.2% B. cepacia, 53.8% B. cenocepacia and 77.2% B. multivorans. Conclusion: Meropenem–vaborbactam and delafloxacin are in vitro active against Bcc and Achr.
Not file

Dates and versions

hal-03978223 , version 1 (08-02-2023)

Identifiers

Cite

Eric Farfour, Louise Ruffier d'Epenoux, Anaëlle Muggeo, Corentine Alauzet, Lise Crémet, et al.. In vitro susceptibility of nonfermenting Gram-negative rods to meropenem–vaborbactam and delafloxacin. Future Microbiology, 2023, ⟨10.2217/fmb-2021-0278⟩. ⟨hal-03978223⟩

Collections

URCA P3CELL
5 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More